A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to Iâ„¢), today announced a ...
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
The pre-B-cell receptor (pre-BCR), which comprises two Igμ chains and two germline-encoded surrogate light chains (SLC) that are associated with the signalling subunits Igα and Igβ, is formed ...
Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...
Mammalian hosts coordinate various cell death pathways as part of the immune defense system against pathogens including ...
T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...
Panel A shows the timeline of clinical events, including chimeric antigen receptor (CAR)–positive T-cell counts in peripheral blood (blue line) and soluble B-cell maturation antigen (BCMA ...
CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
A fungal infection has been shown to trigger a fruit fly's own immune system to destroy brain cells leading to signs of neurodegeneration, a new study has found.
Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback